ADC Therapeutics SA (ADCT) stock
ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.37+0.02 (+1.48%)
Close on Nov 18, 2026Market cap $174.91MP/E –Yield –
ADC Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
ADC Therapeutics's revenue for the twelve months ending Sep 30, 2026 was $84.87M, up 12.8% year over year. For fiscal 2025 it was $81.36M, up 14.9% from the year before. The highest annual figure on record is $209.91M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.36M | +14.9% |
| FY2024 | Dec 31, 2024 | $70.84M | +1.8% |
| FY2023 | Dec 31, 2023 | $69.56M | -66.9% |
| FY2022 | Dec 31, 2022 | $209.91M | +518.9% |
| FY2021 | Dec 31, 2021 | $33.92M | – |
| FY2020 | Dec 31, 2020 | $0 | -100.0% |
| FY2019 | Dec 31, 2019 | $2.34M | +105.3% |
| FY2018 | Dec 31, 2018 | $1.14M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $21.72M | +32.2% |
| Q2 FY2026 | Jun 30, 2026 | $19.25M | +2.2% |
| Q1 FY2026 | Mar 31, 2026 | $20.85M | -9.5% |
| Q4 FY2025 | Dec 31, 2025 | $23.06M | +36.4% |
| Q3 FY2025 | Sep 30, 2025 | $16.43M | -11.0% |
| Q2 FY2025 | Jun 30, 2025 | $18.84M | +8.2% |
| Q1 FY2025 | Mar 31, 2025 | $23.03M | +27.6% |
| Q4 FY2024 | Dec 31, 2024 | $16.91M | +0.7% |
| Q3 FY2024 | Sep 30, 2024 | $18.46M | +27.4% |
| Q2 FY2024 | Jun 30, 2024 | $17.41M | -9.7% |
| Q1 FY2024 | Mar 31, 2024 | $18.05M | -4.9% |
| Q4 FY2023 | Dec 31, 2023 | $16.79M | -75.9% |
| Q3 FY2023 | Sep 30, 2023 | $14.49M | -81.0% |
| Q2 FY2023 | Jun 30, 2023 | $19.28M | +11.5% |
| Q1 FY2023 | Mar 31, 2023 | $18.99M | -59.2% |
| Q4 FY2022 | Dec 31, 2022 | $69.80M | +310.3% |
| Q3 FY2022 | Sep 30, 2022 | $76.32M | +480.5% |
| Q2 FY2022 | Jun 30, 2022 | $17.29M | +359.9% |
| Q1 FY2022 | Mar 31, 2022 | $46.50M | – |
| Q4 FY2021 | Dec 31, 2021 | $17.01M | – |
| Q3 FY2021 | Sep 30, 2021 | $13.15M | – |
| Q2 FY2021 | Jun 30, 2021 | $3.76M | – |
| Q1 FY2021 | Mar 31, 2021 | $0 | – |
| Q4 FY2020 | Dec 31, 2020 | $0 | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
See a number that looks wrong?